Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Olufunmilayo Olopade
University of Chicago
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Lagos State University Teaching Hospital
Ikeja, Lagos, Nigeria
ABIODUN POPOOLARecruiting - Lagos University Teaching Hospital
Yaba, Lagos, Nigeria
ANTHONIA SOWUNMIRecruiting - Obafemi Awolowo University Teaching Hospitals Complex (oauthc)
Ile-Ife, Osun State, Nigeria
Recruiting - University of Ibadan Hospital
Ibadan, Oyo State, Nigeria
ATARA NTEKIMRecruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 18 Mar 2025
- Primary completion
- 1 Jul 2034
- Completion
- 1 Jul 2036
- Last update posted
- 17 Feb 2026
- Registered enrollment
- 74
- Registry id
- NCT06348134
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.